Pharvaris N.V.
corporate_fare Company Profile
Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek monitors PHVS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- FDA Accepts Pharvaris' NDA for HAE Drug Deucrictibant IR, Sets April 2027 PDUFA Date
- Pharvaris Confirms H1 2026 NDA Submission for HAE Treatment, Details 2025 Financials and Recent $124M Capital Raise
- Pharvaris Extends Cash Runway Into 2028 After Offering Closes
- Pharvaris Secures $124M Net from Offering, Extends Cash Runway to 2028, Reports Improved Q1 Loss
- Pharvaris Closes $132.3M Public Offering, Including Full Over-Allotment Exercise
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for PHVS, detected from its recent SEC filings · based on capital-structure filings through 2026-05-08.
Offering Priced · Capital Raised
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.